[ Ref ID: 25 ] Address - GB -London,
The market for therapeutic monoclonal antibodies is one of the most dynamic sectors within the pharmaceutical industry. Next generation antibodies are forecast to drive the market towards a high level innovation in early-stage discovery and several potential niche busters set to launch in the next 5 years. This will allow the large market to continue to record robust growth. This is an opportunity since MAb Market is strong and expected to GROW stronger.
:
Held over three days, The Next Generation of Antibody Engineering Technologies and Antibody Therapeutics Development meeting brings together key industry and academic experts, which gives delegates an extensive knowledge into the successful implementation of antibody engineering and therapeutic area case studies in antibody discovery, design, engineering areas and how to effectively apply these biotherapeutics in the clinic to envisage which new innovative therapies to achieve market successes.
Event Format
Day One , Comprise of extensive networking opportunities starts with opening ceremony drinks then followed with dinner. Participants will also be brief on the conference outline.-
Day Two , Will provide you with latest developments relating to pre-clinical and clinical R&D on therapeutics antibodies. Presentations is based on practical aspect through case studies and interactive panel discussions.
Day Three , Will focus on recent trends and innovations of antibody technologies and engineering. Presentations is based on practical aspect through case studies and interactive panel discussions.
What will be discussed?
Priority issues we have identified include:
• Pre-clinical and Phase I clinical data on a novel anti-tumour antibody-1L-12 fusion protein
• IMGT® databases and tools for antibody engineering and humanization
• Generation of therapeutic antibodies against cancer targets with a low risk of clinical immunogenicity
• Improving antibody properties and affinity by semi-rational in silico engineering, a realistic perspective
• Strategies for the Optimization of Therapeutic Antibodies
• Generation of gene-engineered chimeric DNA antibodies by recombinant technologies for specific therapy of autoimmune diseases.
• Raxibacumab for the Treatment of Inhalational Anthrax
• Using intracellular domain antibodies to block protein-protein interactions in cancer
• Therapeutic IgG4 antibodies engage in Fab-arm exchange with patient's IgG4 in vivo
• Sym004, an anti-EGFR antibody mixture with a unique mechanism of action
• Bispecific T Cell-engaging Antibodies for Cancer
• Improving antibody properties and affinity by semi-rational in silico engineering, a realistic perspective
• In silico Aggregation Screening and Antibody Engineering methodologies to Improve Developability and Safety Profile
• High affinity monoclonal Antibodies lamprey VLR
Who will attend?
VPs, Directors, Heads, Engineers, Experts and Managers of:
• Pharmaceuticals
• Research & Development companies
• Antibody and Protein Engineering
• Preclinical Development & Research
• Clinical Development & Research
• Antibody Development
• Immunology (Research)
• Immunogenicity
• IP/ Patents
• New Product Development
• Business Development
• Technology and Equipment providers
• Solution Providers / Biotechs
• Governments and Regulators
• Academics and Professional Associations
More Information
For more information about The Next Generation of Antibody Engineering Technologies and Antibody Therapeutics Development Conference, please contact:
Sarah Adams
InnoQube Ltd
Telephone: +421 944 263926
Email: sarah.adams@inno-qube.com
Participation Price:
For more information about the price please call us tel:+421 944 263926
Images